ABSTRACT
@#Abstract: The demand for reliable toxicological data of chemicals runs through every link of occupational health work. The prevention of occupational diseases involves high requirements for the standardization of chemical toxicity assessment in occupational health institutions. Good laboratory practice (GLP) emphasizes the integrity of the test process to trace and supervise the whole process of the test, which is conducive to the standardization of chemical toxicity identification. Therefore, the standardized construction of GLP laboratories is an important starting point for occupational health institutions to carry out chemical toxicity identification. In the construction and management process of GLP laboratories for chemical toxicity identification, occupational health institutions need to build a sound organization and operation system, carry out systematic training and assessment of personnel, establish standard operating norms and emphasize their importance, strengthen the management of facility environment and laboratory, pay attention to quality control and process supervision, and constantly improve their own ability level. To actively adapt to social development and market demand, to provide strong support for occupational health work.
ABSTRACT
OBJECTIVE@#To study the influence of cisplatin implants on transplantation tumor growth and the expression of tissue kallikrein-7 (KLK7) and E-cadherin (E-cad) in tumor-bearing mice with gastric cancer.@*METHODS@#BALB/c nude mice were collected as experimental animal and were randomly divided into model control group (Group A), tail intravenous injection of cisplatin group (Group B), intratumor injection of cisplatin group (Group C) and cisplatin implants treatment group (Group D). After the drugs intervening, the weight and volume of transplantation tumors were measured on Day 20, Day 30 and Day 40 and serum and KLK7 and E-cad contents in transplanted tumor tissue were examined.@*RESULTS@#On Day 20, Day 30 and Day 40 after treatment, the weight and volume of transplantation tumors of tumor-bearing mice in four groups were different (Group A > Group B > Group C > Group D). The contents of KLK-7 and E-cad in tumor tissue and serum of tumor-bearing mice in four groups were different (Group A > Group B > Group C > Group D in KLK-7) and (Group A < Group B < Group C < Group D in E-cad). The weight and volume, and KLK7 and E-cad contents of transplantation tumors in four groups were significant difference (P < 0.05).@*CONCLUSION@#Cisplatin implants can inhibit the growth of transplanted tumor tissue and down-regulated KLK7 expression and up-regulated E-cad expression of tumor-bearing mice with gastric cancer.
ABSTRACT
Objective To study the influence of cisplatin implants on transplantation tumor growth and the expression of tissue kallikrein-7 (KLK7) and E-cadherin (E-cad) in tumor-bearing mice with gastric cancer. Methods BALB/c nude mice were collected as experimental animal and were randomly divided into model control group (Group A), tail intravenous injection of cisplatin group (Group B), intratumor injection of cisplatin group (Group C) and cisplatin implants treatment group (Group D). After the drugs intervening, the weight and volume of transplantation tumors were measured on Day 20, Day 30 and Day 40 and serum and KLK7 and E-cad contents in transplanted tumor tissue were examined. Results On Day 20, Day 30 and Day 40 after treatment, the weight and volume of transplantation tumors of tumor-bearing mice in four groups were different (Group A > Group B > Group C > Group D). The contents of KLK-7 and E-cad in tumor tissue and serum of tumor-bearing mice in four groups were different (Group A > Group B > Group C > Group D in KLK-7) and (Group A < Group B < Group C < Group D in E-cad). The weight and volume, and KLK7 and E-cad contents of transplantation tumors in four groups were significant difference (P < 0.05). Conclusion Cisplatin implants can inhibit the growth of transplanted tumor tissue and down-regulated KLK7 expression and up-regulated E-cad expression of tumor-bearing mice with gastric cancer.
ABSTRACT
OBJECTIVE@#To explore the expression and clinical significance of DKK-1 protein in patients with gastric cancers.@*METHODS@#Enzyme linked immuno sorbent assay was used to detect expressions of serum DKK-1 protein in 90 cases of gastric cancers, 50 cases of gastric benign disease and 40 healthy cases. The dynamic change in serum DKK-1 protein of gastric cancer patients who accepted radical operation for a month was also observed.@*RESULTS@#The expression of serum DKK-1 protein in gastric cancer groups was significantly higher than that in gastric benign group's (P < 0.01) and in health control (P < 0.01). Serum DKK-1 level was increased gradually along with the progress of the disease. Serum DKK-1 levels were significantly higher in patients at TNM staging III and IV than patients at TNM staging I and II. Level of serum DKK-1 was related to microvascular invasion, differentiation degree and infiltration depth. Level of serum DKK-1 was significantly reduced in patients after radical surgery (P < 0.01).@*CONCLUSIONS@#The expression of serum DKK-1 protein in gastric cancer patients is increased. Level of serum DKK-1 is related to TNM staging, microvascular invasion, differentiation degree and infiltration depth. DKK-1 detection can be used as a reference index in monitoring gastric cancer progress and biological behavior.
ABSTRACT
Objective: To explore the expression and clinical significance of DKK-1 protein in patients with gastric cancers. Methods: Enzyme linked immuno sorbent assay was used to detect expressions of serum DKK-1 protein in 90 cases of gastric cancers, 50 cases of gastric benign disease and 40 healthy cases. The dynamic change in serum DKK-1 protein of gastric cancer patients who accepted radical operation for a month was also observed. Results: The expression of serum DKK-1 protein in gastric cancer groups was significantly higher than that in gastric benign group's (P < 0.01) and in health control (P < 0.01). Serum DKK-1 level was increased gradually along with the progress of the disease. Serum DKK-1 levels were significantly higher in patients at TNM staging III and IV than patients at TNM staging I and II. Level of serum DKK-1 was related to microvascular invasion, differentiation degree and infiltration depth. Level of serum DKK-1 was significantly reduced in patients after radical surgery (P < 0.01). Conclusions: The expression of serum DKK-1 protein in gastric cancer patients is increased. Level of serum DKK-1 is related to TNM staging, microvascular invasion, differentiation degree and infiltration depth. DKK-1 detection can be used as a reference index in monitoring gastric cancer progress and biological behavior.